{"id":480814,"date":"2020-04-22T17:52:01","date_gmt":"2020-04-22T17:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480814"},"modified":"2020-04-22T17:52:01","modified_gmt":"2020-04-22T17:52:01","slug":"cart-cell-therapy-market-for-nonhodgkin-lymphoma-is-expected-to-touch-usd-27962-million-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cart-cell-therapy-market-for-nonhodgkin-lymphoma-is-expected-to-touch-usd-27962-million-by-2030_480814.html","title":{"rendered":"CAR-T cell therapy Market for Non-Hodgkin Lymphoma is expected to touch USD 2796.2 Million by 2030"},"content":{"rendered":"
\"CAR-T<\/a><\/p>\n
\n
CAR T-Cell Therapy Market for Non-Hodgkin lymphoma<\/div>\n<\/div>\n<\/div>\n
The CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma market size from 2017 to 2030 segmented by US and EU markets. <\/div>\n

DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) – Market Insights and Market Forecast-2030<\/a>’ report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) and market trends in the 6MM, i.e., the United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).<\/p>\n

CAR-T cell therapy market for NHL <\/strong><\/p>\n

The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market size from 2017 to 2030 segmented by US and EU markets. The Report also covers current CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Marketed<\/strong> Therapies in CAR-T cell therapy market for NHL <\/strong><\/p>\n

Chemotherapies, radiation therapies and immunotherapies are either used in combination or alone, depending upon the severity, success rate, age and several other factors. However, CAR-T cell therapy promises one-time treatment and cancer-free life. The available therapeutics treatment options in CAR T-Cell Therapy market for Non-Hodgkin lymphoma aim to kill the leukemia cells in the blood and bone marrow.<\/p>\n

The approval of Yescarta<\/strong> was proved to be the light of the day for the group of cancer patients who were left with a few other options, and those with certain types of lymphoma that had not responded to previous treatments.<\/p>\n

\"\"<\/a><\/p>\n

Emerging Therapies in CAR-T cell therapy market for NHL <\/strong><\/p>\n

This section focusses on the rate of uptake of the potential CAR T-Cell Therapies recently launched in the Non-Hodgkin’s lymphoma market or expected to get launched in the market during the study period 2017–2030. The analysis covers Non-Hodgkin’s lymphoma market uptake by CAR T-Cell Therapies; patient uptake by therapies; and sales of each therapy.<\/p>\n

The approval of the novel CAR-T cell therapy attracted many pharma investors and pharma companies, highlighting the bright scope of CAR-T cell therapies in oncology.<\/p>\n

Several companies, including Celgene<\/strong>, and Gilead<\/strong>, are working to fuel the CAR-T cell therapy market for Non-Hodgkin lymphoma. The expected launch of Lisocabtagene maraleucel<\/strong> (also known as JCAR017) of Celgene<\/strong>’s, (a BMS company) and KTE-X19 <\/strong>by Gilead<\/strong> will significantly drive the NHL market in the near future.<\/p>\n

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Non-Hodgkin’s lymphoma (NHL) emerging CAR T-Cell Therapies.<\/p>\n

Request for Sample Pages<\/a><\/p>\n

CAR-T cell therapy market for NHL: Forecast <\/strong><\/p>\n

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.<\/p>\n

 <\/p>\n

Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.<\/p>\n

Know more about the scenario of CAR-T Market for NHL<\/a><\/p>\n

Scope of the Report <\/strong><\/p>\n